Bioline RX Ltd  

(Public, NASDAQ:BLRX)   Watch this stock  
Find more results for BLRX
+0.01 (0.44%)
Feb 26 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 2.25 - 2.37
52 week 1.20 - 3.08
Open 2.25
Vol / Avg. 234,748.00/300,370.00
Mkt cap 89.18M
P/E     -
Div/yield     -
EPS     -
Shares 1.00
Beta 2.50
Inst. own     -
May 19, 2015
BioLine RX Ltd at Biocentury BioEquity Europe Add to calendar
Mar 24, 2015
BioLine RX Ltd Extraordinary Shareholders Meeting - 5:00AM EDT - Add to calendar
Mar 17, 2015
Q4 2014 BioLine RX Ltd Earnings Release (Estimated) Add to calendar
Mar 9, 2015
BioLine RX Ltd at EBD Group BIO-Europe Spring Add to calendar
Mar 8, 2015
BioLine RX Ltd at ROTH Capital Annual ROTH Conference Add to calendar
Feb 10, 2015
BioLine RX Ltd at Biotechnology Industry Organization CEO & Investor Conference - Webcast
Feb 10, 2015
BioLine RX Ltd at Biotechnology Industry Organization CEO & Investor Conference - Webcast
Jan 12, 2015
BioLine RX Ltd at EBD Biotech Showcase - Webcast
Jan 12, 2015
BioLine RX Ltd at JPMorgan Healthcare Conference
More events from DailyFinance »    


19 Hartum Street, P.O.Box 45158
+972-2-5489100 (Phone)
+972-2-5489101 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


BioLine RX Ltd is an Israel-based company engaged in the development of therapeutics, from preclinical-stage development to advanced clinical trials, for a range of medical needs. Its clinical therapeutic candidates under development consist of BL-1020 that is in Phase II/III clinical trials to improve cognitive function in schizophrenia patients; BL-1040, which is under pivotal CE-Mark registration trial for the prevention of cardiac remodeling following an acute myocardial infarction; BL-5010, which has completed Phase I/II clinical trials for non-surgical removal of skin lesions; BL-1021 that has completed Phase Ia clinical trial for the treatment of neuropathic pain or pain that results from damage to nerve fibers, and BL-7040, a synthetic oligonucleotide, which is in Phase II clinical trial for the treatment of inflammatory bowel disease. The Company also has 11 pre-clinical stage development products for various indications.

Officers and directors

Aharon Schwartz Chairman of the Board
Age: 71
Bio & Compensation  - Reuters
Kinneret Savitsky Ph.D. Chief Executive Officer, Director
Age: 46
Bio & Compensation  - Reuters
Philip A. Serlin Chief Financial Officer, Chief Operating Officer
Age: 52
Bio & Compensation  - Reuters
Moshe Phillip M.D. Vice President of Medical Affairs and Senior Clinical Advisor
Age: 59
Bio & Compensation  - Reuters
David Malek Vice President - Business Development
Age: 35
Bio & Compensation  - Reuters
Leah Klapper General Manager, BioLine Innovations Jerusalem
Bio & Compensation  - Reuters
Michael J. Anghel Director
Age: 75
Bio & Compensation  - Reuters
Jacob Friedman Director
Age: 44
Bio & Compensation  - Reuters
Raphael Hofstein Director
Age: 63
Bio & Compensation  - Reuters
Sandra Panem Ph.D. Director
Age: 67
Bio & Compensation  - Reuters